TG Therapeutics, Inc. Expected to Post FY2025 Earnings of $0.72 Per Share (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at B. Riley lowered their FY2025 earnings estimates for TG Therapeutics in a research report issued to clients and investors on Wednesday, May 1st. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn $0.72 per share for the year, down from their prior forecast of $0.78. B. Riley has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.08) per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.53 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $3.46 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. TG Therapeutics’s revenue for the quarter was up 713.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.28) EPS.

Several other research firms have also recently commented on TGTX. HC Wainwright upped their target price on shares of TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. The Goldman Sachs Group lifted their target price on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. LADENBURG THALM/SH SH upped their price target on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday, April 18th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.83.

TG Therapeutics Stock Down 1.4 %

TGTX opened at $16.19 on Friday. The business has a 50 day moving average of $15.25 and a 200-day moving average of $14.41. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 70.39 and a beta of 2.33. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $35.67.

Institutional Trading of TG Therapeutics

A number of large investors have recently bought and sold shares of the stock. Pingora Partners LLC bought a new position in shares of TG Therapeutics during the fourth quarter valued at $27,000. PNC Financial Services Group Inc. increased its position in shares of TG Therapeutics by 131.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares in the last quarter. NBC Securities Inc. bought a new position in TG Therapeutics during the 3rd quarter valued at about $58,000. Anchor Investment Management LLC acquired a new position in TG Therapeutics in the fourth quarter valued at about $80,000. Finally, REDW Wealth LLC bought a new stake in TG Therapeutics during the third quarter worth about $84,000. 58.58% of the stock is currently owned by institutional investors.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the transaction, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 9.20% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.